HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Show Significant Survival Benefits in MET-Driven Lung Cancer

What happened

On Aug. 17, 2026, HUTCHMED announced positive results from the SAFFRON Phase III trial. The combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with EGFR-mutated NSCLC with MET overexpression or amplification who progressed on prior TAGRISSO®.

Why it matters

This is the first global Phase III trial to show significant PFS and OS benefits in this setting. It addresses MET-driven resistance, which affects one in three patients, and provides the first biomarker-directed, all-oral treatment option for this population.